Homeoprotein Msx1-PIASy Interaction Inhibits Angiogenesis

Myung Jin Son1, Seung Bae Rho2, Kwangbae Kim3

  • 1Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea.

Cells
|August 14, 2020
PubMed

Insights

The homeoprotein Msx1 inhibits tumor growth by blocking blood vessel formation (angiogenesis). Its interaction with PIASy protein is crucial for this anti-angiogenic effect, suggesting new therapeutic targets.

Area of Science:

  • Molecular Biology
  • Oncology
  • Developmental Biology

Background:

  • The homeoprotein Msx1 was previously shown to inhibit tumor growth via apoptosis.
  • Tumor growth is dependent on angiogenesis, the formation of new blood vessels.
  • Msx1's role in inhibiting angiogenesis remained unexplored.

Purpose of the Study:

  • To investigate the role of Msx1 in angiogenesis.
  • To elucidate the molecular mechanisms underlying Msx1-mediated anti-angiogenic effects.

Main Methods:

  • Overexpression and siRNA-mediated silencing of Msx1 in human umbilical vein endothelial cells (HUVECs).
  • In vivo studies using mouse muscle tissue and the chicken chorioallantoic membrane (CAM) assay.
  • Yeast two-hybrid screening to identify Msx1-interacting proteins.
  • Reporter assays to assess vascular endothelial growth factor (VEGF) activity.

Main Results:

  • Msx1 overexpression inhibited angiogenesis in HUVECs and mouse models.
  • Silencing Msx1 abrogated its anti-angiogenic properties.
  • PIASy (protein inhibitor of activated STAT Y) was identified as a Msx1-interacting protein, stabilizing Msx1 and enhancing its anti-angiogenic function.
  • Msx1 suppressed VEGF reporter activity.

Conclusions:

  • Msx1 functions as an inhibitor of angiogenesis.
  • The interaction between Msx1 and PIASy is critical for Msx1's anti-angiogenic activity.
  • This interaction pathway represents a potential target for anti-cancer therapies.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.3K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K